Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR440234 |
Synonyms | |
Therapy Description |
SAR440234 is a bispecific T-cell engager (BiTE) antibody that targets the CD3 antigen on T cells and CD123 on tumor cells, which may result in increased T cell activation, and enhanced anti-tumor response leading to tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR440234 | SAR-440234|SAR 440234 | SAR440234 is a bispecific T-cell engager (BiTE) antibody that targets the CD3 antigen on T cells and CD123 on tumor cells, which may result in increased T cell activation, and enhanced anti-tumor response leading to tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03594955 | Phase Ib/II | SAR440234 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Terminated | USA | FRA | 0 |